---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-102570"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2026-08-28T10:00:29+00:00"
generated_at: "2026-08-28T10:10:07.024444+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# BioXcel files Chapter 11, sells assets to Teva for $57.5M upfront plus milestones

## Summary
- Filed Chapter 11 petitions on Aug 27, 2026 in Delaware; operates as debtor-in-possession.
- DIP financing from Oaktree and QIA: up to $19M new money plus $58.25M roll-up.
- Stalking Horse APA with Teva: $57.5M upfront, up to $67.5M development milestones, up to $20M commercial milestones.
- Appointed Samir Saleem as Chief Restructuring Officer, reporting to Board's Strategic Process Committee.
- Sale subject to higher bids and court approval; transaction target close by Oct 30, 2026.

## SEC filing metadata
- accession: 0001104659-26-102570
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2026-08-28T10:00:29+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 1.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465926102570/0001104659-26-102570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465926102570/tm2624233d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-102570
- JSON: https://secwatch.observer/filing/0001104659-26-102570.json
- Plain text: https://secwatch.observer/filing/0001104659-26-102570.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.